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Background:  The Killip classification was developed for simple risk stratification of myocardial infarction in 1967. Killip class 4 (cardiogenic 
shock) is well known to be the strongest predictor of hospital mortality in ACS-patients. However, little is known about outcome of ACS-patients 
presenting with Killip classes 2 and 3 in current clinical practice.
Methods:  Between Oct 2006 and Oct 2008, consecutive patients with ACS were enrolled into the Euro-Heart-Survey ACS-Registry to document 
treatment and hospital complications. We examined the impact of Killip class at admission on outcome of STEMI and of NSTE-ACS in clinical 
practice in Europe.
Results:  Out of 19,158 patients with ACS, 7,652 had STEMI (40%). Of STEMI-patients 3.9% had cardiogenic shock (Killip 4) as compared to only 
1.2% of NSTE-ACS-patients. Pulmonary congestion (Killip 2 or 3) was present in 16.9% of STEMI and in 17.2% of NSTE-ACS. Patients in Killip 2 or 3 
were less likely to undergo reperfusion therapy for both STEMI and NSTE-ACS as compared to patients in Killip 1 or 4. Hospital mortality was highest 
in cardiogenic shock, but already was significantly increased in Killip classes 2 and 3.
Conclusion: Still today, the Killip classification first described in 1967, continues to be a simple and valid tool to risk-stratify patients with STEMI 
as well as with NSTE-ACS with a steady increase of mortality in clinical practice with increasing Killip class. 
STEMI
Killip 1
n=6,059
Killip 2
n=978
Killip 3
n=320
Killip 4
n=295
Age 62 71 73 69
Female 26.3 % 35.1 % 41.3 % 34.9 %
Fibrinolysis 18.5 % 17.6 % 18.7 % 14.2 %
Primary PCI 74.9 % 61.3 % 45.2 % 59.3 %
Hospital Mortality 2.9 % 13.6 % 27.4 % 50.5 %
NSTE-ACS
Killip 1
n=9,392
Killip 2
n=1,461
Killip 3
n=519
Killip 4
n=134
Age 67 75 76 75
Female 35.1 % 42.8 % 45.3 % 40.3 %
Early PCI (<48h) 48.0 % 32.6 % 32.4 % 46.3 %
Hospital Mortality 1.5 % 5.5 % 9.8 % 35.8 %
